文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

一种将水凝胶间隔物放置、直肠周围间隙创建与前列腺立体定向体部放疗中直肠剂量学相关联的新模型

A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
PubMed 文献 · Radiat Oncol · 2018-10-01

研究纳入20例低中危前列腺癌患者,于2015至2017年放置SpaceOAR水凝胶后接受36.25 Gy/5次立体定向体部放疗,提出角度θ与水凝胶体积乘积这一新参数,发现其与直肠剂量学指标相关性强于单独参数,且随访14个月无>2级直肠毒性。

要点

  • 水凝胶放置最佳位置为前列腺中部腺体中线和正中线。
  • 新参数θ×水凝胶体积与直肠剂量学获益相关性强于单独θ或体积。
  • 随访14个月无>2级直肠毒性,低级别毒性见于三分之一患者并在1个月内缓解。

核心结论

  • 最佳水凝胶放置位于前列腺中部腺体、中线处。
  • 新参数θ×水凝胶体积可解释水凝胶放置带来的大部分直肠剂量学获益,并可用于评估水凝胶放置的学习曲线现象。

研究设计与样本

  • 研究纳入20例低、中危前列腺癌男性患者,于2015年至2017年接受水凝胶放置。
  • 患者接受立体定向体部放疗,总剂量36.25 Gy,分5次。
  • 在CT模拟扫描的3个轴位层面(中部腺体、中部腺体上方1 cm、下方1 cm)评估水凝胶对称性。
  • 测量水凝胶体积和由前列腺、水凝胶与直肠形成的角度θ,并计算θ与水凝胶体积的归一化乘积。
  • 分析这些参数与直肠周围距离、直肠最大1-3 cc点剂量(rDmax 1-3 cc)及直肠接受处方剂量80-95%的体积(rV80-95%)的相关性,并按RTOG标准记录急性直肠毒性。

主要发现

  • 50%的患者在全部3个CT模拟扫描轴位层面上水凝胶双侧对称放置至中线1 cm以内。
  • 任一轴位层面上水凝胶侧方不对称<2 cm不影响直肠剂量学,但下方轴位层面无水凝胶导致rDmax 1 cc平均增加171 cGy(p < 0.005)。
  • 前列腺中部腺体中线处测量的直肠周围距离(均值9.1 ± 4.3 mm)与rV95强相关(R2 0.6,p < 0.001)。
  • 水凝胶体积均值和θ分别为10.3 ± 4.5 cc和70 ± 49°。
  • 直肠周围距离、rV95和rDmax 1 cc与角度θ相关(p < 0.01),与新指标θ×水凝胶体积相关性更强(p < 0.001)。

关键数值与推荐

  • 水凝胶放置对称性评估:5例患者中在全部3个轴位层面双侧对称至中线1 cm以内(原文为50%)。
  • 下方轴位层面无水凝胶导致rDmax 1 cc平均增加171 cGy(p < 0.005)。
  • 直肠周围距离均值9.1 ± 4.3 mm与rV95相关(R2 0.6,p < 0.001)。
  • 水凝胶体积均值10.3 ± 4.5 cc,角度θ均值70 ± 49°。
  • 直肠周围距离、rV95和rDmax 1 cc与θ相关(p < 0.01),与θ×水凝胶体积相关性更强(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SpaceOAR hydrogel is employed to limit rectal radiation dose during prostate radiotherapy. We identified a novel parameter - the product of angle θ and hydrogel volume - to quantify hydrogel placement. This parameter predicted rectum dosimetry and acute rectal toxicity in prostate cancer patients treated with stereotactic body radiotherapy to 36.25 Gy in 5 fractions. METHODS: Twenty men with low- and intermediate-risk prostate cancer underwent hydrogel placement from 2015 to 2017. Hydrogel symmetry was assessed on the CT simulation scan in 3 axial slices (midgland, 1 cm above midgland, 1 cm below midgland). Two novel parameters quantifying hydrogel placement - hydrogel volume and angle θ formed by the prostate, hydrogel, and rectum - were measured, and the normalized product of θ and hydrogel volume calculated. These were then correlated with perirectal distance, rectum maximum 1-3 cc point doses (rDmax 1-3 cc), and rectum volumes receiving 80-95% of the prescription dose (rV80-95%). Acute rectal toxicity was recorded per RTOG criteria. RESULTS: In 50% of patients, hydrogel placement was symmetric bilaterally to within 1 cm of midline in all three CT simulation scan axial slices. Lateral hydrogel asymmetry < 2 cm in any one axial slice did not affect rectum dosimetry, but absence of hydrogel in the inferior axial slice resulted in a mean increase of 171 cGy in the rDmax 1 cc (p < 0.005). The perirectal distance measured at prostate midgland, midline (mean 9.1 ± 4.3 mm) correlated strongly with rV95 (R2 0.6, p < 0.001). The mean hydrogel volume and θ were 10.3 ± 4.5 cc and 70 ± 49°, respectively. Perirectal distance, rV95 and rDmax 1 cc correlated with hydrogel angle θ (p < 0.01), and yet more strongly with the novel metric θ*hydrogel volume (p < 0.001). With a median follow up of 14 months, no rectal toxicity >grade 2 was observed. Low grade rectal toxicity was observed in a third of men and resolved within 1 month of SBRT. Men who had these symptoms had higher rDmax 1 cc and smaller θ*hydrogel volume measurements. CONCLUSIONS: Optimal hydrogel placement occurs at prostate midgland, midline. The novel parameter θ*hydrogel volume describes a large proportion of rectum dosimetric benefit derived from hydrogel placement, and can be used to assess the learning curve phenomenon for hydrogel placement.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hwang ME, Black PJ, Elliston CD, et al. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy. Radiat Oncol. 2018. PMID: 30285812. doi:10.1186/s13014-018-1135-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。